Latest Jazz Pharmaceuticals News & Updates

See the latest news and media coverage for Jazz. We track all announcements, press releases, and industry mentions in real time, all in one place.

Jazz Pharmaceuticals (Jazz)

Global biopharmaceutical company developing medicines for unmet needs

jazzpharma.com

Headquarters: Dublin, Ireland
Founded year: 2003
Company type: Public company
Number of employees: 3,500–5,000
Industry: Pharmaceuticals

Last updated Today

Latest news about Jazz Pharmaceuticals (Jazz)

In short: Jazz Pharmaceuticals reported record revenues and secured FDA approval for Ziihera while expanding its rare disease pipeline.

Company announcements

September 15 Jazz

Jazz completes acquisition of Actio Biosciences

The deal strengthens Jazz's neuroscience portfolio, particularly for rare epilepsies like KCNT1+ DEE, by integrating precision medicine expertise to advance drug development.

August 31 Jazz

Jazz Pharmaceuticals Reports Ziihera Survival Benefits in GEA Trial

Ziihera plus chemotherapy showed statistically significant overall survival benefits versus trastuzumab. The FDA recently approved this regimen for first-line HER2+ advanced gastroesophageal adenocarcinoma treatment.

February 24 Jazz

Jazz reports record full year 2025 revenues of $4.3 billion

Fourth quarter revenue reached $1.2 billion while the company provides 2026 guidance forecasting total revenues between $4.25 and $4.50 billion.

February 24 Jazz

Jazz files annual 10-K report for 2025

The filing submitted on February 24, 2026 covers the fiscal year ended December 31, 2025 and provides a comprehensive company overview.

Media coverage

August 26 Financial Times

Jazz Pharmaceuticals Announces Pricing of Upsized Private Offering of $1.1 Billion of 1.875% Exchangeable Senior Notes due 2032 and Concurrent Ordinary Share Repurchases

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) (" Jazz Pharmaceuticals ") announced the pricing of $1.1 billion aggregate principal amount of 1.875% exchangeable senior notes due 2032...

August 26 Forbes

Is Jazz Pharmaceuticals Stock Undervalued At $110?

Jazz Pharmaceuticals (NASDAQ: JAZZ) is currently trading at approximately $110, having decreased by 11% year-to-date, even after a significant positive development with the conditional European...

August 26 PR Newswire

Jazz Pharmaceuticals Announces Pricing of Upsized Private Offering of $1.1 Billion of 1.875% Exchangeable Senior Notes due 2032 and Concurrent Ordinary Share Repurchases

DUBLIN, Aug. 27, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) ("Jazz Pharmaceuticals") announced the pricing of $1.1 billion aggregate principal amount of 1.875% exchangeable...

August 25 Seeking Alpha

Jazz wins FDA nod for cancer therapy developed with BeOne, Zymeworks

Jazz Pharmaceuticals (JAZZ) stock rises as the FDA approves the company's cancer therapy developed with BeOne Medicines (ONC) and Zymeworks (ZYME). Read more here.

Never miss news about Jazz

Track Jazz and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Jazz competitors & trending companies

Browse news for competitors to Jazz and other trending companies.